1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

06 Mar 2024
Admin
News Article

Clobetasol Propionate Ophthalmic Suspension Gets Approval

FDA Approves Clobetasol Propionate Ophthalmic Suspension for Post-Operative Pain after Ocular Surgery

Overview

Today, Formosa Pharmaceuticals (6838.TWO), headquartered in Taiwan, in partnership with AimMax Therapeutics based in the United States, announced a significant milestone: the U.S. Food and Drug Administration (FDA) has granted approval for their clobetasol propionate ophthalmic suspension 0.05% (APP13007). This approval paves the way for its use in treating post-operative inflammation and pain following ocular surgery.

A unique Formulation

Derived from Formosa Pharma’s proprietary APNT™ nanoparticle formulation platform, this innovative product marks the first FDA-approved ophthalmic clobetasol propionate medication and the first new steroid introduced in over 15 years in the ophthalmic market.
Its unique formulation offers patients a convenient dosing regimen (twice daily for 14 days without tapering), promising swift and sustained relief from inflammation and pain.
Results from two Phase 3 clinical trials demonstrated its superiority over placebo, both statistically and clinically (p<0.001).

Surgeries & Market

With approximately seven million ocular surgeries performed annually in the United States, this novel eyedrop enters a lucrative market estimated at $1.3 billion for topical ophthalmic steroids and steroid combinations.

Thank You Employees: Formosa Pharmaceuticals CEO

Erick Co, President and CEO of Formosa Pharmaceuticals, expressed gratitude towards AimMax Therapeutics for their instrumental role in guiding the program to success, alongside acknowledging the dedication of their employees and support from collaborators.
Co emphasized that FDA approval serves as a springboard for global expansion, with plans to collaborate with U.S. commercialization partner Eyenovia, Inc., to reach ophthalmologists and patients.
Simultaneously, they aim to explore opportunities in additional territories and advance their pipeline projects.

Words from CEO: AimMax Therapeutics

Laurene Wang, Ph.D., Founder and CEO of AimMax Therapeutics, congratulated Formosa Pharma on this achievement, highlighting the collaborative effort to bring this innovative formulation to market and its potential to benefit millions of patients undergoing ocular surgery.

From Eyenovia

• Michael Rowe, CEO of Eyenovia, expressed enthusiasm about the addition of clobetasol propionate ophthalmic suspension 0.05% to their commercial product portfolio, emphasizing its potential to capture a significant share of the market due to its favorable posology and profile compared to other post-surgical steroid options.

• Eyenovia is gearing up for a robust mid-year launch of this product, aiming to capitalize on the estimated $1.3 billion annual market opportunity.